trending Market Intelligence /marketintelligence/en/news-insights/trending/_8ZEpYYOprAhxgvrpc1PUQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

UnitedHealth's OptumRx to merge with specialty pharmacy Diplomat

Gauging Supply Chain Risk In Volatile Times

Part Two IFRS 9 Blog Series: The Need to Upgrade Analytical Tools

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

2018 US Property Casualty Insurance Market Report


UnitedHealth's OptumRx to merge with specialty pharmacy Diplomat

UnitedHealth Group Inc.'s OptumRx Inc. will merge with Michigan-based specialty pharmacy Diplomat Pharmacy Inc.

OptumRx will acquire Diplomat's outstanding common stock for $4.00 per share through a cash tender offer and assumption of outstanding debt. Based on an outstanding share count of 75,770,397 as of Nov. 8, the per-share price implies a stock valuation of $303.1 million.

Diplomat provides specialized infusion therapies in all 50 states and the District of Columbia. It had launched a strategic review with a view to a possible sale or merger in August, having seen its shares plunge more than 56% in a day when it announced Feb. 22 that it would delay its fourth-quarter and full-year 2018 financial results.

It later recorded a full-year 2018 loss attributable to the company of $302.3 million, mainly driven by a $262 million noncash impairment charge within its pharmacy benefit management segment and a $46 million noncash impairment charge related to its specialty segment.

The deal was unanimously approved by the specialty pharmacy's board.